[August 17, 2017]

Covalon To Feature IV Clear at APHON Pediatric Conference

Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that it will be featuring IV Clear while exhibiting for the first time at the 41^st Association of Pediatric Hematology/Oncology Nurses annual conference and exhibit at the Palm Springs Convention Center, from August 17-19, 2017.

Along with IV Clear, Covalon will feature its proprietary line of infection management dressings for both the perioperative and vascular access fields. The unique, dual antimicrobial silicone adhesive technology used in the IV Clear™ and SurgiClear™ brands not only help to reduce the risk of infection, but also greatly diminish the likelihood of developing a medical adhesive related skin injury (MARSI), a clinically relevant and potentially avoidable event.

"IV Clear provides pediatric patients and clinicians with a virtually pain-free dressing change experience, while providing advanced antimicrobial protection," said John R. Hands, Executive Vice President. "We often hear from parents and nurses about how long and stress inducing a dressing change can be for children. With our line of antimicrobial silicone adhesive products, these concerns are effectively eliminated."

Covalon's IV Clear™ antimicrobial clear silicone adhesive securement dressing is indicated to cover and protect vascular access devices used in a wide variety of both acute and alternate care settings. Its patented combination of chlorhexidine and silver is proven to have a synergistic effect against some of the most commonly associated blood stream infection bacteria¹ and its skin sparing silicone adhesive will not cause adhesive related skin injury or pain during dressing changes².

APHON is the professional organization for pediatric hematology/oncology nurses and other pediatric hematology/oncology healthcare professionals. Its members are dedicaed to promoting optimal nursing care for children, adolescents, and young adults with cancer and blood disorders, and their families. To learn more about IV Clear, visit Covalon at booth 225 during exhibit hours, or email [email protected]

About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

¹ A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American Journal of Infection Control , Volume 43 , Issue 6 , S22
² A Human Repeat Patch Test Study, DiTizio et al. http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters

View source version on businesswire.com: http://www.businesswire.com/news/home/20170817005518/en/

[ Back To TMCnet.com's Homepage ]